KA
ALT icon

Kovack Advisors’s Altimmune ALT Stock Holding History

Kovack Advisors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Buy
36,250
+1,035
+3% +$4.39K 0.01% 973
2025
Q4 		$127K Buy
+35,215
New +$154K 0.01% 978

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Kovack Advisors's ALT Position: Q1 2026 in Review

Kovack Advisors increased its Altimmune (ALT) stake by 2.9% in Q1 2026, buying an estimated $4.39K and bringing the position to 36,250 shares worth $112K. The position accounts for 0.01% of the portfolio, ranked #973.

Kovack Advisors first reported a position in ALT in Q4 2025 and has held it in 2 quarters since. The position peaked at $127K in Q4 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Kovack Advisors held 36,250 shares of Altimmune worth $112K as of Q1 2026.
  • Kovack Advisors bought 1,035 Altimmune shares in Q1 2026, an estimated $4.39K.
  • Altimmune made up 0.01% of Kovack Advisors's portfolio in Q1 2026, its #973 holding.
  • Kovack Advisors first reported a position in Altimmune in Q4 2025 and has held it in 2 quarters since.
  • Kovack Advisors's Altimmune position peaked at $127K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.